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Abstract 
Cathepsin B and matrix metalloproteinase (MMP) play key roles in tumor progression by 
controlled degradation of extracellular matrix. Consequently, these proteases have been 
attracted in cancer research, and many imaging probes utilizing these proteases have been 
developed. Our groups developed cathepsin B and  MMP imaging  nanoprobes based on 
polymer nanoparticle platform. Both cathepsin B and MMP imaging probes used near-infrared 
fluorescence (NIRF) dye and dark-quencher to for high sensitivity, and protease-sensitive 
peptide sequence in each probe authorized high specificity of the probes. We compared the 
bioactivities of cathepsin B and MMP sensitive probes in cancer-related environments to 
investigate the biological property of the probes. As a result, cathepsin B probe showed 
fluorescence recovery after the probe entered the cytoplasm. This property could be useful 
to evaluate the cytoplasmic targeted delivery by using probe-conjugated nanoparticles in vivo. 
On the other hand, MMP probe was superior in specificity in vivo and tissue study. This 
comparative study will provide precise information about peptide-based optical probes, and 
allow their proper application to cancer diagnosis. 
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Introduction 
Recently  molecular  imaging  has  been  greatly 
progressed  for  biomedical  application,  and  the  ex-
pression  or  activity  of  specific  enzymes  including 
protease  can  be  monitored  by  molecular  imaging 
techniques  [1-3].  Especially,  near-infrared  fluores-
cence  (NIRF)  imaging  with  small  animals  has  been 
widely studied in the last decade due to its relatively 
deep  tissue  penetration.  Various  NIRF  imaging 
probes  were  designed  and  applied  for  diagnosis  of 
diseases,  and  some  of  them  are  enzyme-sensitive 
probes which can change their signal intensity in re-
sponse to specific enzymes in targeted site [4-9]. These 
probes can monitor the enzymatic activities, and they 
also can be used as an efficient optical contrast agent 
for  enzyme  rich  target  site.  Importantly,  many  en-
zymes, such as caspases, secretases, furin, phospha-
tases, and other proteases have been major targeted 
for optical probe [10-13], because they are expressed 
in tissues with pathological changes. They also have 
various biological mechanisms and catalytic activities 
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related with progression of disease like inflammation, 
immune disorder, and tumors. Especially, in cancer 
imaging, monitoring the activity of specific protease is 
closely relevant to tumor progression. 
Several proteases, including cathepsin B, uroki-
nase-type  plasminogen  activator,  and  matrix  metal-
loproteinases (MMPs) are involved in tumor progres-
sion [14, 15]. Among them, MMPs are family of met-
alloproteinases  which  need  zinc  ion  essentially  on 
their active-sites. Most MMPs are initially secreted as 
inactivated  forms  (proMMPs),  and  proMMPs  are 
converted  functionally  active  forms  in  extracellular 
space.  Collagenase-1  (MMP-1),  collagenase-2 
(MMP-8),  and  collagenase-3  (MMP-13)  are  typical 
MMPs, and they actively participate in tissue remod-
eling for tumor progression [16, 17]. Moreover, MMPs 
also play an essential role in survival of cancer cells 
[18],  and  they  are  overexpressed  in  various  cancer 
including colon, pancreas, and breast cancers [19-21]. 
On the other hand, cathepsin B  is another protease 
that plays key roles in growth, migration, invasion, 
and metastasis of cancer cells [22, 23]. This lysosomal 
cysteine  protease  is  overexpressed  in  cancer  cells, 
such as gastric or colon cancers [24, 25]. Squamous cell 
carcinoma  cells  (SCC-7)  was  also  confirmed  that  it 
express  high  levels  of  cathepsin  B  [26,  27].  Because 
overexpressed MMPs and cathepsin B play important 
biological functions in tumor, many imaging probes 
targeting  these  proteases  have  been  developed  for 
cancer diagnosis [28, 29]. 
We  developed  two  different  protease-sensitive 
optical probes which showed enhanced fluorescence 
signal  intensity  by  cathepsin  B  and  MMPs,  respec-
tively [6, 7, 30]. When these probes were exposed to 
the  specific  proteases  at  the  tumor  region,  they  in-
duced sensitive and specific fluorescence recovery in 
tumor.  Our  two  probes  adopted  similar  structural 
design  with  NIR  fluorochrome  and  dark  quencher. 
Both probes utilized quenching/dequenching system 
with fluorochrome dye and dark quencher to provide 
superior sensitivity, but the dequenching conditions 
of two probes could be distinguished from each other 
for biological properties of each target protease. The 
understanding of the precise dequenching conditions 
of each probe is important to make an accurate cancer 
diagnosis.  Furthermore,  appropriate  application  of 
each  protease-sensitive  optical  probe  could  provide 
more valuable information in cancer research.  
Most studies had been focused on the chemical 
properties of single probe, and only a few compara-
tive studies related with the biological property of the 
probes had been performed. However, understanding 
the  biological  properties  and  differences  in 
dequenching condition of probes are important to use 
the probes appropriately. Herein, we investigated and 
described  the  behaviors  of  two  specific  prote-
ase-sensitive  probes  under  the  various  conditions 
including cell culture  supernatant, in vitro, in vivo, 
and  ex  vivo.  We  compared  two  parallel  designed 
probes with different target protease under the iden-
tical  conditions,  and  this  comparative  study  on  the 
two probes is expected to provide advantages of each 
probe and to guide their proper application in cancer 
diagnosis. 
Materials and methods 
Preparation of cathepsin B and MMP probes  
Cathepsin B-sensitive NIRF probe (cathepsin B 
probe) and MMPs-sensitive NIRF probe (MMP probe) 
were prepared as previously described [6, 7]. Briefly, 
each probe was synthesized by conjugating NIR flu-
orochrome  (Cy5.5)  and  dark  quencher  (black  hole 
quencher-3,  BHQ-3)  to  a  cathepsin  B-sensitive 
(Gly-Arg-Arg-Gly-Lys-Gly-Gly) or a MMPs-sensitive 
(Gly-Pro-Leu-Gly-Met-Arg-Gly-Leu-Gly-Lys)  sub-
strate  protein.  The  substrate  peptides  were  synthe-
sized by standard solid-phase Fmoc peptide chemis-
try  (Peptron,  Daejeon,  Korea).  The  final  probe  was 
characterized  by  analytical  reverse  phase-high  per-
formance liquid chromatography (RP-HPLC; Purity: 
>95%), UV-Vis spectra, and matrix-assisted laser de-
sorption/ionization-time of flight mass spectrometry 
(MALDI-TOF MS) [7].  
To confirm the correlation of the probe activities 
with the protease concentration, each probe (20 nM) 
was  incubated  with  various  concentrations  of  each 
protease  in  the  sterile  96-well  microplate  (Greiner 
Bio-One, Tokyo, Japan). After incubation of the mi-
croplate at 37 ºC for 30 minutes, the fluorescence in-
tensity was measured with a Kodak Imaging Station 
4000 MM (New Haven, CT).  
Immunocytochemistry and NIRF signal recovery 
of probes in cultured cells 
To  confirm  the  colocalization  of  each  protease 
expression  and  probe  signal  in  cellular  level,  im-
munocytochemistry  using  MMP-13  or  cathepsin  B 
antibody was performed after probe treatment. The 
MMP  probe  was  confirmed  to  be  dequenched  by 
various  types  of  MMP  including  MMP-2  and 
MMP-13, and we selected MMP-13 antibody because 
the MMP probe was more sensitive to MMP-13 than 
other MMPs [6].  
Murine  squamous  cell  carcinoma  cells  (SCC-7) 
were obtained from the American Type Culture Col-
lection (Rockville, MD) and used in this study. The 
cells were cultured in RPMI 1640 media (Gibco, Grand 
Island, NY) containing 10% fetal bovine serum (FBS) Theranostics 2012, 2(2) 
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(Gibco,  Grand  Island,  NY)  and  1%  penicil-
lin/streptomycin  at  37  °C  in  a  humidified  5%  CO2 
atmosphere. SCC-7 cells were seeded at a density of 
5×104 cells/dish in 35 mm cover-glass bottom dishes 
and incubated for 36 hours. After incubation, cathep-
sin B probe (200 nM) or MMP probe (200 nM) was 
added  into  each  culture  dish  and  incubated  for  3 
hours.  Subsequently,  the  cells  were  rinsed  with 
phosphate buffered saline (pH 7.4, PBS) and fixed in 
3.5  %  paraformaldehyde  in  PBS  for  10  minutes  at 
room temperature (RT). The antigens were retrieved 
in 95°C antigen retrieval buffer (100mM Tris, 5% urea, 
pH 0.5) for 10 minutes. After 3-times of washes, the 
cells were permeablized in 0.25% Triton X-100 in PBS 
for  5  minutes  at  RT.  The  permeabilized  cells  were 
incubated with 1% bovine serum albumin in PBS for 
30  minutes  to  block  unspecific  binding  of  the  anti-
bodies and each dish was incubated in the 1:200 di-
luted  anti-cathepsin  B  mouse  IgG  (Abcam,  Cam-
bridge, MA) or anti-MMP-13 mouse IgG (Calbiochem, 
Nottingham, UK) for 2 hours. We used the cells which 
omitted each primary antibody as a negative control. 
The  anti-mouse  IgG-FITC  (1:1,500  dilution;  Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) was applied 
to each dish for 40 minutes in dark condition. After 3 
times  of  wash  in  PBS,  the  nuclei  of  the  cells  were 
stained  with  DAPI.  The  fluorescence  images  were 
observed  with  IX81-ZDC  focus  drift  compensating 
microscope with FITC and Cy5.5 filters at 600× mag-
nification (Olympus, Tokyo, Japan). 
NIRF recovery of the probes in cell culture su-
pernatant 
To compare the activities  of two probes in ex-
tracelluar  space,  cell  supernatant  was  collected  and 
reacted  with  various  concentrations  of  each  probe. 
First-passaged  SCC-7  cells  were  cultured  until  con-
fluence, and then switched to serum-free medium for 
20 hours before the harvest of cell culture supernatant. 
Then, 90 μl aliquot of supernatant was reacted with 
various concentrations (from 3.125 nM to 50 nM) of 
cathepsin B or MMP probe in the sterile 96- well mi-
croplate (Greiner Bio-One, Tokyo, Japan). As a control 
experiment, the same amount (90 μl) of distilled water 
was also reacted with identical concentrations of each 
probe and compared with the result of reacted culture 
supernatant. The 96-well microplate was incubated at 
37 ºC for 30 minutes, and the fluorescence intensity 
was monitored using a Kodak Imaging Station 4000 
MM (New Haven, CT) equipped with filter set for Cy 
5.5 after incubation. The excitation wave length was 
set at 675 nm and emission spectra recorded from 680 
to 720 nm. The signal intensity was acquired from the 
fluorescence image sections of a microplate. The NIRF 
intensity  was  expressed  as  a  mean  intensity  of  se-
lected area. 
In vivo NIRF Imaging of the probes injected tu-
mor bearing mice 
To evaluate the dequenching of probes in vivo, 
SCC-7 tumor-bearing nude mice (5 weeks old, n=5 per 
each group, Institute of Medical Science, Tokyo) were 
prepared. SCC-7 cells (1106 cells/mouse) suspended 
in 50 μl sterile  media were injected subcutaneously 
into the left flank of mice. When the diameter of tu-
mors reached approximately 7.0 ± 0.5 mm in size, 100 
μl of cathepsin B probe (1 mg/ml of saline) or MMP 
probe (1 mg/ml of saline) was injected intravenously 
via a tail vein. After intravenous injection, the NIRF 
signals were non-invasively monitored using the eX-
plore Optix imaging system (ART Advanced Research 
Technologies  Inc.,  Montreal,  Canada)  as  previously 
described [31]. Imaging was performed 1, 3, 6, 9, and 
12 hours post injection, and the acquired images were 
assessed  with  an  Analysis  Workstation  (ART  Ad-
vanced Research Technologies Inc.). For the compar-
ison of fluorescence intensity at tumor of cathepsin B 
or MMP probe injected mice, paired t-test was used. 
All  animal  care  and  experimental  procedures  were 
performed  in  compliance  with  the  Institutional 
guidelines of Korea Institute of Science and Technol-
ogy  (KIST)  and  the  relevant  laws,  and  institutional 
committees have approved the experiments. 
Immunohistochemistry and NIRF signal recov-
ery of probes in organ and tissues  
To further assess the NIRF signal intensity in the 
body, one mouse of each group was euthanized at the 
time point that the NIRF signal at the tumor showed 
peak  intensity.  Then,  tumors  and  other  visceral  or-
gans from each mouse were excised to acquire ex vivo 
NIRF  images  with  KODAK  image  station.  After  in 
vivo and ex vivo imaging, tumor and major internal 
organs are divided into 2 pieces. The one was fixed in 
neutral buffered formalin and embedded in paraffin, 
and the other piece was embedded in optimum cut-
ting temperature tissue compound (OCT compound, 
Sakura, Tokyo) for cryosection preparation. 
Immunohistochemistry (IHC) using cathepsin B 
and MMP-13 antibodies is performed to confirm the 
accordance of NIRF signal recovery of probe and ca-
thepsin B or MMP expression in tissues. Routine IHC 
was performed using 6 μm-thick sections of formalin 
fixed and paraffin embedded tissues. The slides were 
deparaffinized and rehydrated, then endogenous pe-
roxidase activities were blocked with 3% H2O2 solu-
tion for 20 minutes. The primary antibodies were ap-
plied for 2 hours RT, and HISTOSTAIN®-PLUS Kit Theranostics 2012, 2(2) 
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(Invitrogen, Carlsbad, CA) was applied following the 
manufacture’s  instruction  to  detect  protein  expres-
sions.  After  the  processes,  each  slide  was  coun-
ter-stained with Harris hematoxylin. 
For  the  evaluation  of  NIRF  signal  recovery  of 
probes in tissues, the 8 m-thick frozen sections were 
prepared  for  fluorescence  microscopic  imaging  of 
probe  dequenching  in  tissues  including  tumor.  The 
slides were observed under the IX81-ZDC focus drift 
compensating microscope with Cy 5.5 filter set with-
out any histological stains. 
Result  
Preparation of cathepsin B and MMP probes  
The NIRF imaging mechanism and structure of 
cathepsin B probe and MMP probe are shown in Fig-
ure 1A and B. On the basis of substrate peptide of 
MMPs and cathepsin B, the probes was prepared by 
conjugation of linker peptides, NIRF dye (Cy5.5), and 
dark quencher (BHQ-3) [6, 7]. The cleavage of linker 
peptides by specific protease induces an activation of 
probe  to  recover  fluorescence  at  target  site  (Figure 
1A). When the inactive form of probes reaches to tar-
get tissues, the activity of target protease can be im-
aged through the cleavage of peptide and recovery of 
their fluorescence.  These activatable probes showed 
high  specificity  and  sensitivity  by  reducing  back-
ground fluorescence. 
We  observed  the  fluorescence  change  of  each 
probe with addition of the target protease (2 to 8 nM). 
After  30  minutes  incubation,  4  nM  of  cathepsin  B 
probe showed 8.9-times higher fluorescence intensity 
than the probe incubated with cathepsin B inhibitor 
(Figure 1C). The MMP probe with 4 nM of MMP-13 
also  showed  8.8-times  higher  fluorescence  intensity 
than  the  probe  incubated  with  MMP-13  inhibitior 
(Figure 1D). The fluorescence intensity of each probe 
was increased according to the increase of the corre-
sponding protease. The cathepsin B probe which was 
incubated with 2, 4, and 8 nM of cathepsin B showed 
13.5, 31.2, and 50.0 times higher fluorescence intensity 
than the probe incubated without cathepsin B. MMP 
probe with 2, 4, and 8 nM of MMP-13 also showed 
13.4, 24.7, and 48.4 times higher fluorescence intensity 
than the probe incubated without MMP-13. 
 
 
Figure 1. (A) NIRF recovery of the cathepsin B and MMP probes by target enzyme. (B) Structural designs of cathepsin B probe and MMP-2 
probe. (C) The NIRF recovery of cathepsin B probe by 2nM, 4nM, and 8 nM of cathepsin B in vitro. (D) The NIRF recovery of MMP probe 
by 2nM, 4nM, and 8 nM of MMP-13 in vitro. Theranostics 2012, 2(2) 
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Figure 2. The cathepsin B expression and the NIRF signal of cathepsin B probe in cultured SCC-7 cells. (A) DIC image of the SCC-7 cells. 
(B) Nuclei of the SCC-7 cells which were stained with DAPI. (C) Cathepsin B expression in the cytoplasm of the cultured SCC-7 cells. (D) 
NIRF signal of the cathepsin B probe in the SCC-7 cells. (E) The coincidence of cathepsin B expression and the probe signal in merged 
image.  
 
Cathepsin B/MMP-13 expression and NIRF signal 
recovery of probes in SCC-7 cells  
In cultured SCC-7 tumor  cells, NIRF signal re-
covery of two probes was closely related with expres-
sion of corresponding protease. Immunocytochemis-
try  demonstrated  the  location  of  cathepsin  B  and 
MMP-13 in probe-treated SCC-7 tumor cells. Cathep-
sin B expression was observed in the cytoplasm of the 
tumor cells (Figure 2). The recovered NIRF signal was 
also  limited  in  the  cytoplasm  and  completely  coin-
cided with cathepsin B expression (Figure 2E). On the 
other hand, intense MMP-13 expression was observed 
in  the  nuclei  of  the  cells  than  cytoplasm,  which  is 
agreed with the NIRF signal recovery of MMP probe 
(Figure 3). No significant cathepsin B/MMP-13 posi-
tive signals were observed in negative control. 
NIRF signal recovery of Cathepsin B and MMP 
probes in cell culture supernatant 
When the various concentrations of cathepsin B 
probes  were  added  to  cell  culture  supernatant,  the Theranostics 2012, 2(2) 
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NIRF signals was not recovered distinctly (Figure 4A). 
The fluorescent signal intensity of cathepsin B probe 
in cell culture supernatant was similar with that in 
distilled water at 50, 25, and 12.5 nM of probe con-
centration. However, MMP probe displayed distinct 
NIRF recovery in cell culture supernatant (Figure 4B). 
At 50 nM of MMP probe concentration, the cell su-
pernatant showed more than 4-fold higher NIRF in-
tensity  compared  to  distilled  water.  The  degree  of 
increased  NIRF  recovery  was  dependent  upon  the 
concentration of added probe. These data showed that 
dequenching condition of two probes in cell culture 
supernatant was definite, which is may be originated 
from the secretion of MMP from cells.  
 
 
Figure 3. The MMP-13 expression and NIRF signal of the MMP probe in cultured SCC-7 cells. (A) DIC image of the SCC-7 cells. (B) 
Nuclei of the SCC-7 cells which were stained with DAPI. (C) MMP-13 expression in the cultured SCC-7 cells. (D) NIRF signal of the MMP 
probe in the SCC-7 cells. (E) The co-localization of MMP-13 expression and MMP probe signal in merged image.  Theranostics 2012, 2(2) 
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Figure 4. NIRF recovery of cathepsin B and MMP probes in cell culture supernatant. (A) Quenching properties and low NIRF recovery 
of cathepsin B probe in culture supernatant at various concentrations of the probe. (B) High NIRF recovery of MMP probe in culture 
supernatant at various concentrations of the probe. fluorescence imaging of 96-well microplate (695 nm).  
 
In vivo NIRF Imaging of cathepsin B/MMP probe 
injected tumor bearing mice 
Figure 5 shows serial images of mice obtained 
for 12 h after intravenous injection of the cathepsin B 
and MMP probes. Cathepsin B probe displayed high-
er fluorescent intensity in tumor site for 12 hours. The 
NIRF at the tumor site of cathepsin B probe injected 
mice  was  gradually  increased  up  to  6  hours  after 
probe  injection  (Figure  5A).  The  MMP  probe  also 
showed  high  and  specific  NIRF  signal  recovery  in 
tumor site of the probe injected tumor-bearing mice. 
Meanwhile,  the  maximum  NIRF  intensity  in  tumor 
site of the MMP probe-injected mice was observed at 3 
hours post injection. The peak fluorescence intensity 
of the cathepsin B and MMP probes injected mice was 
significantly  different  (p<0.05),  and  the  gap  of  the 
time  point  showing  maximum  NIRF  intensity  was 
that MMP probes were activated 3 hours earlier than 
cathepsin B probes in vivo. 
Cathepsin B/MMP-13 expressions and NIRF sig-
nal recovery of probes in tumor and other organs  
The ex vivo images were closely correlated with 
the in vivo images, and they reconfirmed that both 
probes  were  dequenched  in  tumor  site  with  high 
specificity. However, notably, the cathepsin B probe 
displayed  relatively  higher  NIRF  signals  in  visceral 
organs including liver and kidney. On the contrary, 
MMP probe had relatively lower signals in the vis-
ceral organs compared to cathepsin B probe (Figure 
6A and B).  
Cathepsin B and MMP-13 expressions in the ex-
cised  organs  including  tumor  were  evaluated  with 
IHC using cathepsin B and MMP-13 antibodies. IHC 
results showed that the considerable amount of tumor 
cells were cathepsin B positive (Figure 6C). The ca-
thepsin B expression and the location of cathepsin B 
probe signals in tumor tissue were coincided in tumor 
tissues (Figure 6D). Cathepsin B expression was not 
found in lung, spleen, and heart tissues, and the NIRF 
signal  recovery  of  cathepsin  B  probes  was  not  ob-
served  in  these  tissues,  either  (data  not  shown). 
However,  the  vascular  endothelial  cells  including 
sinusoidal  capillaries  of  the  liver  were  cathepsin  B 
positive in the IHC results (Figure 6E), while the cy-
toplasm of hepatocytes did not express cathepsin B. 
Regardless  of  the  cathepsin  B  expression  in  blood 
vessels, the unexpected NIRF recovery was diffusely 
observed  in  the  liver  tissues  including  hepatocytes 
(Figure 6F).  Theranostics 2012, 2(2) 
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Figure 5. In vivo NIRF tomographic images of subcutaneous SCC7 tumor-bearing mice after intravenous injection of cathepsin B and 
MMP probes. (A) The NIRF in the tumor site of the cathepsin B probe injected mouse. (B) The NIRF in the tumor site of the MMP probe 
injected mouse. (C) Comparison of the NIRF intensity at tumor site of cathepsin B and MMP probe-injected mice (p < .05). 
 
 
Figure 6. NIRF signal of cathepsin B and MMP probes in excised SCC7 tumors and other visceral organs. (A) Representative ex vivo NIRF 
imaging of cathepsin B probe and MMPs injected tumor bearing mice scarified at fluorescence intensity peak time. (B) Comparison of the 
NIRF intensity of two probes in visceral organs and tumor. (C) Cathepsin B expression in the cytoplasm of the tumor cells (brown). 
Immunohistochemistry (IHC); horse radish peroxidase and diaminobenzidine (HRP-DAB)/hematoxylin. (D) NIRF of cathepsin B probe in 
tumor tissue (red). Fluorescence imaging; 695 nm. (E) Cathepsin B negative hepatocytes and cathepsin B stained vascular endothelia in 
liver. (F) NIRF of cathepsin B probe in liver tissues. (G) Diffusely stained tumor cells with MMP-13 antibody. (H) NIRF of MMP probe in 
tumor tissue (I) MMP-13 negative hepatocytes. (J) Low NIRF recovery of MMP probe in liver tissues. 
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The disagreement of cathepsin B expression and 
cathepsin B probe signals in liver tissues suggested 
that  cathepsin  B  probe  can  be  dequenched  by 
non-specific factors. In tissue study, the cathepsin B 
probe showed relatively low specificity.  
MMP-13 expression in tumor tissue was identi-
fied in the tumor cells diffusely (Figure 6G), and the 
MMP probe signal was detected in the tumor site with 
agreement  (Figure  6H).  The  lung,  kidney,  spleen, 
heart, and liver (Figure 6I) did not express MMP-13, 
and dequenching of MMP probe by non-specific en-
zymatic activities was not observed in the liver tissue 
(Figure 6J). The MMP probe was different from the 
cathepsin B probe in probe activities in visceral organs 
including liver.  
Discussion 
Our  MMP  and  cathepsin  B  probes  showed  an 
excellent sensitivity based on quenching/ dequench-
ing system with fluorochrome dye (Cy 5.5) and dark 
quencher (BHQ-3). They showed significantly lower 
fluorescent  backgrounds  comparing  to  conventional 
FRET system. This is because BHQ-3 is a strong ab-
sorber of Cy-5.5 and has no native fluorescence, which 
is an efficient quencher of Cy5.5 for the development 
of  NIRF  probes  [32].  Therefore,  both  strongly 
quenched probes could provide high contrast images 
by  dequenching  in  response  to  target  proteases  at 
tumor. The dequenched cathepsin B probe and MMP 
probe showed up to 50.0- and 48.4-times higher fluo-
rescence intensity than quenched one in vitro. More-
over,  we  confirmed  that  each  probe  showed  a  pro-
portional  relation  between  recovered  fluorescence 
signal and different concentrations of corresponding 
protease (2, 4 and 8 nM) (r2=0.97). 
Although  both  probes  demonstrated  superb 
specificity to cancer-related cathepsin B or MMPs, the 
dequenching  of  the  probes  by  target  protease  was 
different depending on the biological environment. In 
cultured  tumor  cells,  cathepsin  B  expression  was 
clearly limited in the cytoplasm of SCC-7 cells. How-
ever, MMP-13 expression was observed in whole tu-
mor  cell  including  strong  MMP-13  positive  nuclei. 
Previously, Roebuck et al. also reported that MMP-13 
expression was identified in the nuclei of the malig-
nant tumor cells [33], and the MMP-13 observed in 
this study was consistent with the result. In spite of 
the different distribution of cathepsin B and MMP-13 
in  cultured  SCC-7  cells,  the  NIRF  recovery  of  each 
probe was dequenched by its target protease expres-
sion in cultured cells. The difference in the localiza-
tion  of  NIRF  signals  may  be  due  to  the  biological 
properties of the cathepsin B and MMP. Cathepsin B 
is the lysosomal protease in the cytoplasm, but MMPs 
are the mostly secreted protease. We further studied 
the activities of two probes in extracelluar milieu. The 
NIRF image of cell culture media reflects the ability to 
activate  probe  in  extracelluar  space  [34].  Thus,  the 
activities of two probes in culture supernatant were 
evaluated, and the  significant recovery of the NIRF 
signals only occurred in the MMP probe treated cell 
culture  supernatant.  Even  at  the  12.5  nM  of  MMP 
probe concentration, MMP probe successfully showed 
fluorescence recovery by MMPs including MMP-13 in 
cell culture supernatant. Because cathepsin B is gen-
erally localized in the cytoplasm, the culture super-
natant of SCC-7 cells contains little or no cathepsin B. 
Therefore, cathepsin B probe maintained in quenched 
state in cell culture supernatant, and the NIRF signals 
were  recovered  in  the  cytoplasm  only  after  cellular 
uptake.  
The obtained maximum NIRF intensity in tumor 
was observed at different time point. The peak fluo-
rescence intensity of cathepsin B probe treated group 
was observed 3 hours later than MMP probe treated 
group, which revealed the location and dequenching 
time of the probe at the target site. The cathepsin B 
probe should be internalized into the cytoplasm and 
encounter the lysosomal enzymes to be dequenched, 
and these steps may require certain amount of time. 
Three hours of delay may be the time for the cathepsin 
B probe to internalize into the cells. 
Another  important  difference  was  found  in  ex 
vivo  imaging.  Although  the  fluorescent  recovery  in 
non-tumor site was not significantly observed during 
in vivo NIRF imaging, the ex vivo NIRF imaging of 
cathepsin B probe injected mice showed unexpected 
fluorescence  recovery  in  liver.  While  the  cultured 
tumor cells are composed of only single type of cells, 
the excised tumor tissue samples contain multiple cell 
populations including stromal, endothelial, and nor-
mal epithelial cells. It is not simple to predict or in-
terpret the dynamics of the probe in vivo, since the 
tumor cells are only the part of the total cell popula-
tion  of  bulk  tumor  samples  [35].  In  addition,  tu-
mor-specificity of the probe in vivo may be decreased, 
if non-tumor cells in any other organs also produce 
the  target  proteases.  Especially,  liver  generally  pro-
duces  various  enzymes  which  can  accidentally  re-
sponse  to  the  probes.  Liver  also  has  an  abundant 
blood supply and blood vessels including sinusoidal 
vessels.  Therefore,  the  specificity  of  probes  in  vivo 
could be estimated by the comparison of fluorescence 
recovery in target site and liver. In this point of view, 
MMP  probe  showed  relatively  higher  specificity  in 
vivo compared to cathepsin B probes. 
Non-specific fluorescence recovery of cathepsin 
B probe in liver was more distinct in tissue study. IHC Theranostics 2012, 2(2) 
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results confirmed that both cathepsin B and MMP-13 
were overexpressed in tumor, but not in the normal 
hepatocytes.  Consequentially,  MMP  probe  was 
dequenched in MMPs rich site of tumor tissue, but no 
NIRF signal recovery was observed in liver tissues. 
On  the  contrary,  non-specific  fluorescence  recovery 
was observed in the liver tissue of cathepsin B probe 
injected mice without any histopathological changes 
of liver. The endothelial cells of sinusoidal vessels and 
hepatic veins were immunoreactive with cathepsin B 
antibody, but hepatocytes were all cathepsin B nega-
tive. It was not clear whether cathepsin B is expressed 
in hepatic vascular endotheila, or there are unknown 
molecules that are similar to the epitope of cathepsin 
B  antibody  in  liver.  Because  of  this  non-specific 
dequenching of cathepsin B probe in liver, we con-
cluded that the MMP probe has higher specificity than 
cathepsin  B  probe  in  ex  vivo  imaging  and  histo-
pathology as well as in vivo condition. 
Due  to  these  different  biological  behaviors  of 
probes  depending  on  various  biological  environ-
ments,  clinical  application  of  the  probes  for  cancer 
diagnosis and therapy would be discriminated from 
each  other.  Extracellular  MMP  can  dequench  the 
MMP  probe  even  before  the  probe  enter  the  cyto-
plasm, and enhanced permeability and retention ef-
fect of tumor vasculature permits accumulation and 
subsequent dequenching of the MMP probe. In other 
words, the MMP probe can exhibit fluorescence re-
covery  immediately  after  reaching  the  tumor  site 
without uptake into tumor cells. In contrast, cathepsin 
B probe can be dequenched to recover its fluorescence 
after  the  probe  enters  the  cytoplasm.  Based  on  this 
property, the cathepsin B probe can be used as a tool 
for evaluating the cytoplasmic delivery of the drugs 
or nanoparticles for cancer therapy in vivo. Intraveo-
nously  injected  drugs  or  nanoparticles  can  be 
non-invasively analyzed by monitoring in vivo NIRF 
imaging  after  cathepsin  B  probe  conjugation.  The 
changes of NIRF intensity would be apparent after the 
cellular uptake of cathepsin B probe conjugated drugs 
or nanoparticles. 
On the other hand, MMP probe showed higher 
specificity in vivo because it was not reactive in other 
visceral organs including liver. Consequently, MMP 
probe  is  more  suitable  to  monitor  whether  probe 
conjugated -drug or -nanoparticle is delivered to the 
target tumor site or not. In addition, considering of 
biological functions of the proteases, MMP probe has 
another advantage of a good indicator for malignant 
tumor. Previous studies suggested that MMPs were 
closely related with malignant tumor [16, 17, 36], and 
the tumor-derived MMPs are intimately involved in 
high malignancy and poor prognoses of various can-
cers [37, 38]. Although both cathepsin B and MMPs 
are  concerned  in  invasion  and  metastasis  of  cancer 
cells, MMPs and the cancer prognosis has been stud-
ied  more  intensively.  Therefore,  in  cancer  research, 
monitoring MMPs with this probe signals may pro-
vide  more  useful  information  related  with  cancer 
progression or predicting the prognosis.  
Conclusion 
In the present study, we compared the different 
dequenching  conditions  of  cathepsin  B  probe  and 
MMP  probe  depending  on  various  biological  envi-
ronments  related  with  cancer.  Both  probes  utilized 
quenched  fluorescence  with  protease-substrate  pep-
tides  to  show  good  specificity  in  tumor,  but  each 
probe showed its own advantages depending on in-
dividual conditions. MMP probe demonstrated supe-
rior specificity in ex vivo imaging and histology, and 
it would be useful for the study of malignant tumor 
and its metastasis. Cathepsin B probe were useful for 
evaluating the cytoplasmic targeted delivery, because 
it was dequenched in the cytoplasm only. With the 
cathepsin B probe, the practical delivery of anti-cancer 
drugs  or  drug  loaded  nanoparticles  into  the  cyto-
plasm  would  be  confirmed  effectively.  This  study 
provides valuable information about the activities of 
two probes in various conditions including cultured 
cell, culture supernatant, in vivo, and tissues. Under-
standing  the  biological  functions  and  biological 
properties of each probe will allow a better use and 
proper application of the probes in cancer theragnosis.  
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